Key result
Empagliflozin is linked to improved diastolic function at three months in patients with HFrEF.
Why the study?
Heart failure with reduced ejection fraction (HFrEF) significantly impacts quality of life and mortality, and the effect of empagliflozin on diastolic function in HFrEF patients needed evaluation.
Does empagliflozin improve diastolic function in patients with heart failure with reduced ejection fraction?
Cohort (n=60)
Yes
Does empagliflozin improve diastolic function in patients with heart failure with reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
Empagliflozin improves echocardiographic markers of systolic and diastolic function in patients with HFrEF after 3 months of treatment.
Background: Patients' quality of life, healthcare utilization, and mortality are all profoundly affected by heart failure (HF), making it a pressing global public health concern. Reduced left ventricular systolic function, typically shown by a left ventricular ejection fraction (LVEF) below 40%, characterizes heart failure with reduced ejection fraction (HFrEF), the most common form of HF. Aim: Evaluation of empagliflozin's impact on diastolic function in individuals with heart failure and reduced ejection fraction. Subjects and methods: This prospective study was conducted from December 2022 to May 2025 in Al-Azhar University Hospitals and Ahmed Maher Teaching Hospital, Cairo, on 60 patients with heart failure with reduced ejection fraction (HFrEF), LVEF<40% either diabetic type 2 or not. Results: The mean left atrial volume index (LAVi) was 51.21±3.76 mL/m², and the left atrial emptying volume (LAEV) averaged 33.43±5.65 mL. The mean left atrial ejection fraction (LAEF) was 31.22±4.28%. In terms of phasic atrial function, reservoir, conduit, and contractile functions were 16.96±1.93%, 11.24±2.19%, and 6.19±1.39%, respectively. Conclusion: Empagliflozin treatment in patients with heart failure with reduced ejection fraction (HFrEF) was associated with marked improvement in cardiac performance and clinical outcomes after three months. A higher ejection fraction and less global longitudinal strain are indicators of the therapy's success in improving left ventricular systolic function. Reductions in the E/e′ ratio and improvements in the size and function of the left atrium are further indicators of its beneficial effects on diastolic function.
No takes yet. Share an insight, caveat, or question.
Atwa et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=60). Empagliflozin was evaluated on Diastolic function. Empagliflozin treatment in patients with HFrEF was associated with improved diastolic function at three months, demonstrating a mean left atrial volume index of 51.21±3.76 mL/m².
Synapse has enriched 10 related papers. Consider them for comparative context: